TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03007537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 10000 IU erythropoietin, subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 0.9% sodium chloride 1ml, subcutaneous injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery
Description: included valve, coronary artery bypass graft or surgery for congenital heart diseases

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cardiac surgery
Description: included valve, coronary artery bypass graft or surgery for congenital heart diseases
Study: NCT04060472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel + oxaliplatin
Description: Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
Study: NCT02615379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPIFLO
Description: Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
Study: NCT04806477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine Consultation
Description: Brief telemedicine consultation, blinded to subsequent face-to-face evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Consultation
Description: Direct face-to-face evaluation (without telemedicine consultation before).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Consultation
Description: Direct face-to-face evaluation (without telemedicine consultation before).
Study: NCT05217056

Intervention type: OTHER
Intervention: measurements
Description: All of the infants with high risk of cerebral palsy will be assessed from birth to 12 months age with the assessments of Prechtl's General movements (GMs) until 20 weeks of age. Also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) will be performed at the 3rd, 6th, and 12th months for the cognitive development.
Study: NCT01914822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill (placebo)
Study: NCT03687021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Different routes of administration of progesterone; Whether there is endometriosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Different routes of administration of progesterone; Whether there is endometriosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Different routes of administration of progesterone; Whether there is endometriosis
Study: NCT04329650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
Study: NCT03840135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyoxidonium 6 mg/ml
Description: Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours).
Study: NCT01416142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureVision2 HD contact lenses
Description: Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Spectacles to be worn throughout 1/2 of an HD movie.
Study: NCT01386879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue
Description: A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue
Description: A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue
Description: A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
Study: NCT05380622

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge.~Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab.

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge.~Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab.
Study: NCT02445989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: Provide NuvaRing to women seeking contraception

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Description: Provide NuvaRing to women seeking contraception
Study: NCT04283487

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructans
Description: 500ml 0.9% normal saline containing 40g fructans

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 500ml 0.9% normal saline containing 40g glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 500ml 0.9% normal saline
Study: NCT01560182

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTL-200 Gene Therapy
Description: Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
Study: NCT02875067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT02059187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1293
Description: MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus™
Description: Lantus™ (insulin glargine \[rDNA origin\]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prandial insulin
Description: Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prandial insulin
Description: Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
Study: NCT02221622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone injection (intravenous solution)
Description: Allopregnanolone intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone injection (intravenous solution)
Description: Allopregnanolone intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone injection (intravenous solution)
Description: Allopregnanolone intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection (intravenous solution)
Description: Placebo intravenous infusion
Study: NCT02156518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises
Description: Vocal Function Exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vocal Hygiene
Description: Vocal Hygiene
Study: NCT02465580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hrIL-2 active
Description: active group: placebo group =1:1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hrIL-2 placebo
Description: active group: placebo group =1:1
Study: NCT02958748

Intervention type: OTHER
Intervention: taking blood sample

Intervention type: OTHER
Intervention: taking blood sample
Study: NCT02001870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro Fecundation (IVF)
Description: In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
Study: NCT02045342

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingest 500ml of placebo prior to metabolic measures.
Study: NCT04980430

Intervention type: DEVICE
Intervention: Virtual Reality
Description: Virtual Reality Demonstration
Study: NCT02001870

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra Uterine Insemination (IUI)
Description: Intra-uterine insemination will be performed according to the usual procedure of each ART center
Study: NCT01019005

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Catheter
Description: Catheter inserted into either perineural tibial nerve or wound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter
Description: Catheter inserted into either perineural tibial nerve or wound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter
Description: Catheter inserted into either perineural tibial nerve or wound
Study: NCT01485510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIFT
Description: An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FACS
Description: A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
Study: NCT03096418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
Study: NCT04380324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).
Study: NCT03933839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainCOACH
Description: PainCOACH is an eight-week, automated, internet-based training in specific pain coping skills (such as progressive muscle relaxation, pleasant imagery and activity pacing), and guided practice with each skill.
Study: NCT01113294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
Study: NCT02197182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUXSOL copper containing cream
Description: Active comparator arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole gel
Description: Active comparator for treatment of bacterial vaginosis
Study: NCT01470586

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery for colorectal cancer
Description: Surgical resection of colorectal cancer
Study: NCT00141531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apaziquone
Description: Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis.
Study: NCT02454309

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02007577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salsalate
Description: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take 3 tablets with breakfast and 4 tablets with dinner
Study: NCT01552044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25mg tablet once a day for 1 month
Study: NCT00120068

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nursing inservices

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Academic detailing to MDs; concurrent review and feedback
Study: NCT03768609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir
Description: Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir
Description: Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
Study: NCT01552044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet once a day for 1 month
Study: NCT02747342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680; SHR3162
Description: SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase.
Study: NCT04351438

Intervention type: DEVICE
Intervention: Active Comparator: centrifuge TPE with citrate
Description: Patients who received citrate-based anticoagulation with centrifuge TPE

Intervention type: DEVICE
Intervention: Active Comparator: Filter TPE with heparin
Description: Patients who received heparin-based anticoagulation with filter TPE

Intervention type: DRUG
Intervention: Active comparator: Filter TPE with citrate
Description: Patients who received citrate-based anticoagulation with filter TPE
Study: NCT02532218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARI-3037MO
Description: Lipid lowering treatment Statins

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARI-3037MO
Description: Lipid lowering treatment Statins
Study: NCT03806985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
Study: NCT03768609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
Study: NCT03806985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Psilocybin
Description: 0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
Study: NCT05535595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genotyping and selection of renin-angiotensin system blocker
Description: One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~* perindopril 4 mg/d after genotyping~* candesartan 8 mg/d after genotyping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: perindopril 4 mg/d without genotyping
Study: NCT04575974

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02751086

Intervention type: PROCEDURE
Intervention: Robotic Gastrectomy
Description: Minimally invasive surgical approach, related to the availability of a robotic surgical system (eg Da Vinci surgical system), that allows a surgeon to perform surgery through a console and dedicated devices.
Study: NCT03806985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Psilocybin
Description: 0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Psilocybin
Description: 0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
Study: NCT01964573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.~Frequency:~Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily
Study: NCT04327466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osciflow
Description: Osciflow is a non-invasive high frequency oscillatory ventilation support delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Highflow
Description: Standard highflow therapy without oscillations delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
Study: NCT04302792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texture-modified foods for cancer patients (Stage 2)
Description: Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste-optimised foods for cancer patients (Stage 3)
Description: Participants (cancer patients with taste \& smell alterations) will be expected to evaluate three foods at home over a period of one month.
Study: NCT03663751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: low-dose decitabine: 5mg/m2 daily for 5 days
Study: NCT02319499

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Alone
Description: Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and Zinc
Description: Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron, Zinc and Vitamin A
Description: Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group received no minerals/vitamin